Aarti Pharmalabs AARTIPHARM
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Research path: Interpret Aarti Pharmalabs's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
AI analysis and Advanced tools for AARTIPHARM
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 3,481.71 | 2,902.43 | 2,582.11 |
| Cash Equivalents | 8.53 | 6.73 | Not available |
| Other Liabilities Total | 7.85 | 8.12 | 6.06 |
| Long Term Debt | 225.17 | 111.26 | Not available |
| Common Stock Total | 45.33 | 45.32 | 45.31 |
| Other Equity Total | 2,079.28 | 1,944.59 | 8.06 |
| Other Current Assets Total | 153.61 | 96.82 | 0 |
| Total Assets | 3,481.71 | 2,902.43 | 2,582.11 |
| Current Portof LT Debt/Capital Leases | 16.55 | 5.09 | 4.49 |
| Cash | 1.09 | 1.91 | 24.07 |
| Total Equity | 2,124.6 | 1,989.91 | 1,757.04 |
| Long Term Investments | 229.28 | 43.27 | 36.78 |
| Total Common Shares Outstanding | 9.07 | 9.06 | 9.06 |
| Tangible Book Valueper Share Common Eq | 220.69 | 208.49 | 185.38 |
| Total Liabilities | 1,357.1 | 912.52 | 825.07 |
| Total Debt | 793.72 | 420.82 | 285.25 |
| Short Term Investments | 0 | 48.72 | 76.68 |
| Cashand Short Term Investments | 9.62 | 57.37 | 100.74 |
| Total Receivables Net | 593.76 | 576.42 | 589.31 |
| Notes Payable/Short Term Debt | 499.82 | 292.8 | 264.06 |
| Deferred Income Tax | 134.33 | 128.4 | 107.92 |
| Accounts Receivable-Trade Net | 583.32 | 575.4 | 519.34 |
| Property/Plant/Equipment Total-Net | 1,706.66 | 1,410.7 | 1,093.19 |
| Total Current Liabilities | 937.57 | 653.07 | 694.39 |
| Total Inventory | 640.31 | 587.58 | 649.44 |
| Accounts Payable | 334.54 | 277.83 | 378.32 |
| Other Currentliabilities Total | 86.66 | 77.35 | 32.26 |
| Total Long Term Debt | 277.35 | 122.93 | 16.7 |
| Intangibles Net | 123.89 | 98.44 | 75.27 |
| Other Long Term Assets Total | 16.81 | 22.75 | 11.33 |
| Note Receivable-Long Term | 7.78 | 7.3 | 18.11 |
| Total Current Assets | 1,397.29 | 1,318.19 | 1,345.64 |
| Capital Lease Obligations | 52.18 | 11.67 | 16.7 |
| Property/Plant/Equipment Total-Gross | Not available | 322.01 | 1,630.04 |
| Goodwill Net | Not available | 1.78 | 1.78 |
| Accumulated Depreciation Total | Not available | Not available | -536.85 |
| Accrued Expenses | Not available | Not available | 15.26 |
| Prepaid Expenses | Not available | Not available | 6.15 |
| Additional Paid-In Capital | Not available | Not available | 440.33 |
| Retained Earnings(Accumulated Deficit) | Not available | Not available | 1,263.34 |
Valuation and ratios
Growth
Debt 5Yr CAGR %755.71
Margins
Operating Margin 12m16.23
Operating Margin 5y Avg17.76
Net Profit Margin 12m10.25
Net Profit Margin 5y10.97
Yield
Dividend Yield %0.51
Valuation
Price to Sale Ratio3.46
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk40.62
Analyst consensus
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Ownership
- Promoter
- 42.86%
- FII
- 8.17%
- MF
- 0.79%
- Other
- 48.18%
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Aarti Pharmalabs Yearly results, Financial Summary The Economic Times
Aarti Pharmalabs Ltd is Rated Sell Markets Mojo
Buy, sell or hold: Hitachi Energy, Union Bank, Aarti Pharmalabs, Coal India, Petronet, Balaji Amines — Ask Profit MSN
Aarti Pharmalabs targets 15-18% revenue and EBITDA growth over 3-4 years scanx.trade
Aarti Pharmalabs Insider Ups Holding During Year simplywall.st
Aarti Pharmalabs Ltd (BOM:543748) Q4 2026 Earnings Call Highlights: Revenue Growth Amidst ... By GuruFocus Investing.com Canada
Events
- board MeetingsQuarterly Results
- dividendRs.2.0000 per share(40%)Final Dividend
- board Meetings(Revised)
- board MeetingsAudited Results & Final Dividend
- dividendRs.1.5000 per share(30%)Interim Dividend
- board MeetingsQuarterly Results & Interim Dividend
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.2.5000 per share(50%)Final Dividend
- board MeetingsQuarterly Results
- board MeetingsAudited Results & Final Dividend
- dividendRs.2.5000 per share(50%)Interim Dividend
- board MeetingsTo consider other business matters.
- board MeetingsQuarterly Results
- annual General MeetingAGM
- board MeetingsQuarterly Results
- dividendRs.1.0000 per share(20%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- dividendRs.2.0000 per share(40%)Interim Dividend
- board MeetingsQuarterly Results & Interim Dividend
Discussion and sentiment for Aarti Pharmalabs
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Community discussion loads as you approach this section.
Business information
What the company does
Aarti Pharmalabs Limited is engaged in the manufacturing of active pharmaceutical ingredients (APIs), advanced intermediates, and xanthine derivatives. The Company also offers comprehensive contract development and manufacturing organization (CDMO) and CMO services for drug substances and new chemical entities (NCE), including their key starting materials (KSM) and regulatory starting materials (RSM), serving various pharmaceutical companies worldwide with a focus on the Ph-I/II/III, launch, and commercial phases. It has dedicated facilities for the production of HPAPIs, corticosteroids, cytotoxic medicines, and oncology products. Its caffeine products include caffeine anhydrous, and caffeine anhydrous (granules). Its range of API products include Ramipril, Quinapril HCL, Budesonide, Bambuterol HCL, Apixaban, Rivaroxaban, Cinacalcet and others. The Company's products are exported to key regulated markets such as the United States (US), the European Union, and Japan.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- AARTIPHARM
- BSE Code
- 543748
Stock FAQ
What is the symbol and ISIN of Aarti Pharmalabs?
Aarti Pharmalabs has the symbol AARTIPHARM and ISIN - INE0LRU01027.
What is the latest recorded price of Aarti Pharmalabs?
The latest available recorded price of Aarti Pharmalabs is INR 693.00 as of 2026-08-06T21:04:53.258Z. This is a source-stamped snapshot, not a live quote.
What are the year high and year low of Aarti Pharmalabs?
Year high: INR 946.45. Year low: INR 583.85.
What is the market capitalization of Aarti Pharmalabs?
Market capitalization: INR 6,302.24 crore.
What is the P/E ratio of Aarti Pharmalabs?
P/E ratio: 28.53.
What is the dividend yield of Aarti Pharmalabs?
Dividend yield: 0.51%.
How is the financial performance of Aarti Pharmalabs based on revenue, net income, and EPS?
Revenue: INR 1,819.44 crore. Net income: INR 174.71 crore. EPS: INR 20.81.
What is the book value of Aarti Pharmalabs?
Book value: INR 220.69.
What are the price-to-book and price-to-sales ratios of Aarti Pharmalabs?
Price-to-book ratio: 3.14. Price-to-sales ratio: 3.46.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.

